Engineered immune cells take aim at tough blood cancers

This study tested whether a new type of immune cell therapy, called CD22 CAR T cells, could be made from patients' own blood cells and safely given to adults with hard-to-treat B-cell leukemia or lymphoma. The main goals were to see if the cells could be produced successfully and to check for serious side effects. 52 participants were enrolled, and the therapy is designed to control the disease rather than cure it, as ongoing management may still be needed.